Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Immunogen-Sponge Hydrogel Reverses TIM-3–Mediated Dendritic-Cell Exhaustion in Alveolar Echinococcosis

ABSTRACT: Alveolar echinococcosis (AE) induces profound dendritic-cell dysfunction characterized by elevated TIM-3 expression and impaired antigen presentation. To overcome parasite-induced immunosuppression, we developed a SHIFT-engineered Immunogen-Sponge hydrogel vaccine incorporating protoscolex-derived antigens (PSAs). Bone marrow-derived dendritic cells (BMDCs) were treated with saline, PSA, F127@PSA, or SHIFT-F127@PSA and subjected to transcriptome sequencing. Comparative transcriptomic analyses were performed to investigate dendritic-cell activation, antigen presentation, immune signaling pathways, and TIM-3-associated regulatory mechanisms.

ORGANISM(S): Mus musculus

PROVIDER: GSE334769 | GEO | 2026/08/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Immunogen-Sponge Hydrogel Reverses TIM-3–Mediated Dendritic-Cell Exhaustion in Alveolar Echinococcosis

Project description:Immunogen-Sponge Hydrogel Reverses TIM-3–Mediated Dendritic-Cell Exhaustion in Alveolar Echinococcosis

| PRJNA1476314 | ENA

Transcription profiling of mouse IgE/antigen-activated mast cells stimulated with TIM-3

Project description:TIM-3 is known to be expressed on dendritic cells, monocytes, melanoma cells, mast cells and on activated Th1 cells. In activated Th1 cells, stimulating TIM-3 by one of its ligands, galectin-9, leads to apoptosis and thus it plays a central role in terminating Th1-type immune responses. Interestingly, in IgE/antigen-activated mast cells TIM-3 enhances the production of IL-13 and IL-4. To get a more complete picture about the gene expression changes induced by TIM-3 in mast cells, in vitro differentiated mouse immature mast cells were stimulated by an agonist anti-TIM-3 antibody and IgE-sensitized mouse immature mast cells were activated by antigen and an agonist anti-TIM-3 antibody for 2 or 16 hours (overnight). Experiment Overall Design: Bone marrow cells were differentiated in RPMI + 10% FCS + 5 ng/ml mouse IL-3 + 40 ng/ml mouse SCF for >4 weeks. The purity of the cell cultures was >90% at this time point (FcERIa+/c-kit+ cells). These in vitro-differentiated immature mast cells were then treated by either control goat IgG or an agonist anti-mouse TIM-3 antibody (RnD Systems, 15 ug/ml for 2 or 16 hours). For the IgE/antigen-activated mouse mast cells, these in vitro-differentiated immature mast cells were sensitized by 5 ug/ml anti-DNP IgE (Sigma) for 1 hour and then treated with 100 ng/ml DNP-HSA (antigen, Sigma) and either control goat IgG or an agonist anti-mouse TIM-3 antibody (RnD Systems, 15 ug/ml) for 2 or 16 hours. The anti-TIM-3 samples were labeled by Cy5 and they were compared to the Cy3-labeled, goat IgG controls in a dual-color, paired experimental setup. The Agilent Whole Mouse Genome 4x44K expression microarray kit and Dual-Color Protocol version 5.5 were used in the experiments.

2009-10-15 | E-GEOD-14438 | biostudies-arrayexpress

Genome-wide profiling of the expression of exosomal circRNAs in patients with hepatic alveolar echinococcosis

Project description:Hepatic echinococcosis (HE) caused by Echinococcus spp. transmitted from carnivores is known as a severe zoonotic disease that formed into hepatic cystic echinococcosis (HCE) and hepatic alveolar echinococcosis (HAE). It continues to be a serious public health issue around the world. HAE is uncommon infection which is characterized by poor prognosis but it is the most life-threatening compare to HCE. Many cases of HAE are recognized at forward stages because clinical symptoms may remain silent in about 10 years of incubation period. Several pathological cases could be observed including septicemia, abscess, recurrent cholangitis, and portal hypertensive gastrointestinal bleeding in untreated people. It is provided that correlated factors includes CD44, Soluble ST2 (sST2), Plasma IL-23, IL-27, and IL-5 for metastasis and prognosis for patients with HAE were identified. However, data on metastatic and prognostic marker are still so poor. Recent studies have revealed that circRNAs are enriched and stable in exosomes. Exosomal circRNAs may be localized in platelet-derived extracellular vesicles, hepatic cells, and pancreatic cancer cells. Studies have suggested that it is possible that cells may transfer circRNAs by excreting them in exosomes. Whereas there are a lot of studies on cancer and other human diseases related exosomal circRNA, no studies on hepatic alveolar echinococcosis-related exosomal circRNAs in humans. Current study provides that exosomal circular RNAs from healthy humans and humans with hepatic alveolar echinococcal disease were detected and characterized using the RNA sequencing.

2022-09-01 | GSE183607 | GEO

Gallus gallus strain:not applicable | isolate:not applicable | breed:white feathered chicken | cultivar:not applicable

Project description:mechanism of antigen presentation of avian dendritic cells

| PRJNA598803 | ENA

The protein repertoires of hydatid fluid from pulmonary cystic echinococcosis

Project description:Echinococcosis is a disease resulting from infection by flatworms of the Echinococcus genus. The vast majority of cystic echinococcosis cases in Southern Brazil are caused by Echinococcus granulosus and Echinococcus ortleppi. Here, we surveyed the protein contents of the hydatid fluid compartment of E. granulosus and E. ortleppi pulmonary bovine cysts, in an attempt to compare their molecular arsenal in this host-parasite interface. We detected some molecular players equally in E. granulosus and E. ortleppi, such as proteolytic enzymes and development signaling molecules, while some activities were more evident in one species, such as apoptosis in E. ortleppi, and cysteine protease activity in E. granulosus.

2022-04-04 | PXD019314 | Pride

Dissection of the immune landscape in Psoriatic Arthritis patients [Mouse scRNA-seq]

Project description:Despite significant advancements in psoriatic arthritis (PsA) treatment modalities, a considerable proportion of patients continue to experience persistent joint inflammation and functional impairment, unresponsive to the armamentarium of biological disease-modifying antirheumatic drugs (bDMARDs) or Janus kinase (JAK) inhibitors. The etiology of resistance in these cases is complex, likely involving intricate immunological and genetic factors which are currently mostly unknown. Identifying novel biomarkers and targets for refractory disease is urgently needed. Here, utilizing single-cell RNA-sequencing of synovial fluid from 41 PsA patients and 9 Osteoarthritis (OA) controls we map the comprehensive immune landscape of PsA. Our analysis reveals major perturbations within the myeloid compartment, identifying distinct cell subsets and altered gene programs in PsA patients. Notably, within the myeloid compartment, refractory patients exhibit elevated expression of interferon- gamma induced gene programs linked to the immunoproteasome and MHC class I antigen presentation, at both the gene and protein level. These results suggest a potential interaction of the immunoproteasome and MHC class I antigen presentation in refractory PsA patients with sustained inflammation. Our research imparts critical insights into PsA pathogenesis, paving the way for both molecular level patient classification and potentially new therapeutic interventions for currently treatment resistant patients.

2025-07-23 | GSE295180 | GEO

Dissection of the immune landscape in Psoriatic Arthritis patients

2025-06-12 | GSE277596 | GEO

Effect of Sec61 inhibitor mycolactone on the proteome of the MutuDC dendritic cell line

Project description:Here we used a newly identified Sec61 blocker, mycolactone, to analyze Sec61 contribution to antigen cross presentation, ERAD and transport of internalized antigens into the cytosol in dendritic cells. Shotgun proteomics were used to asses the broad-ranging effects of Sec61 blockade on dendritic cells and its effect on critical proteins required for antigen presentation and ERAD.

2017-07-11 | PXD006103 | Pride

The effect of TIM-3 stimulation on the gene expression profile of IgE/antigen-activated mouse mast cells

2009-10-01 | GSE14438 | GEO

Proteomic analysis of regulated dendritic cell endosomes reveals dynamic adaptation to antigen uptake and cross-presentation

Project description:MHC class I cross-presentation involves final proteolytic peptide processing by the endosomal insulin-regulated aminopeptidase (IRAP). Reasoning that analysis of the IRAP proximal proteome may inform about dynamic remodeling of a key cross-presentation compartment during antigen uptake, we developed a proximity biotinylation system by expressing a Turbo-ID-IRAP fusion protein in MuTuDCs, a cell line resembling murine type 1 conventional dendritic cells. Analysis of luminal proteins associated with IRAP at steady state and during phagocytosis revealed a massive shift upon uptake of yeast but not apoptotic cells, favoring enrichment of antigen-processing machinery, MHC class I molecules, and proteins involved in ER-associated folding and trafficking. Importantly, Sec22b modulated this proteomic landscape promoting localization of MHC-I cross-presentation proteins (e.g., MHC class I, TAP1, Wdfy4, transferrin receptor) to the IRAP environment, while its absence favored MHC-II and ER-related proteins, suggesting a Sec22b-dependent dichotomy between pathways favoring cross-presentation versus antigen degradation. Intriguingly, uptake of apoptotic cells failed to promote cross-presentation but induced two proteins related to immune tolerance, suggesting potential adaptation of proteome modulation to outcome of antigen presentation. These data suggest that IRAP+ endosomes serve as adaptive hubs integrating secretory and endocytic pathways, with Sec22b acting as a key determinant in tailoring this compartment for MHC-I-mediated cross-presentation.

2026-02-09 | PXD067092 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data